Reflex Sympathetic Dystrophy Diagnosis | AETNA Coverage Update

Summary: Aetna, a CVS Health company, modified CPB 0147 covering reflex sympathetic dystrophy (RSD) diagnosis and treatment, effective April 1, 2026. Here's what billing teams need to do before that date.

CPB 0147 Aetna governs coverage for reflex sympathetic dystrophy — also called complex regional pain syndrome (CRPS) — including how Aetna evaluates medical necessity for diagnostic workups and treatment interventions. This policy update signals a review of Aetna's RSD/CRPS coverage policy criteria, and billing teams managing chronic pain or neurology claims need to audit their documentation standards now. The policy does not list specific CPT, HCPCS, or ICD-10 codes in the data available, but the clinical scope of RSD billing is wide — and the financial exposure is real.

Quick-Reference Table

Aetna Reflex Sympathetic Dystrophy Coverage Criteria and Medical Necessity Requirements 2026

Reflex sympathetic dystrophy — more commonly documented today as complex regional pain syndrome (CRPS Type I or Type II) — is a chronic pain condition that generates significant claims volume across pain management, neurology, and physical medicine practices. Aetna's coverage policy for RSD has historically required tight medical necessity documentation, and this April 1, 2026 modification means those standards deserve a fresh look.

The core issue with RSD billing is that the diagnosis itself is largely clinical. There's no single definitive test. That creates friction at the payer level — Aetna, like most major insurers, scrutinizes whether the documentation actually supports the diagnosis criteria before approving procedures or ongoing treatment.

For medical necessity, Aetna's RSD coverage policy typically requires documented evidence of the condition consistent with established diagnostic criteria — historically the Budapest Criteria, which require a combination of sensory, vasomotor, sudomotor/edema, and motor/trophic signs and symptoms. If your providers aren't explicitly mapping clinical findings to these criteria in their notes, your claims are at risk regardless of what the modified policy says.

Prior authorization is a real concern here. Many of the interventions used in RSD/CRPS management — spinal cord stimulation, sympathetic nerve blocks, ketamine infusions — carry prior authorization requirements under Aetna plans. A modification to CPB 0147 can shift which interventions require prior auth, what documentation Aetna needs to approve them, and how long authorizations remain valid. Pull your current prior authorization workflows and confirm they still align with the post-April 1, 2026 criteria.

The policy modification also affects reimbursement indirectly. If Aetna tightens or reclassifies any interventions as experimental or investigational under CPB 0147, claims that previously sailed through will start generating denials. That's not a hypothetical — it's a pattern you've seen with other chronic pain policies over the past two years.

If your practice has a significant Aetna payer mix and treats RSD/CRPS patients, talk to your compliance officer before April 1, 2026 to confirm your documentation templates and prior auth triggers are updated.

Aetna Reflex Sympathetic Dystrophy Exclusions and Non-Covered Indications

This is where RSD billing gets complicated — and where most claim denial risk lives.

Aetna has historically classified several interventions used in RSD/CRPS treatment as experimental, investigational, or unproven. These include treatments like low-level laser therapy, graded motor imagery (in some plan variants), and certain infusion protocols. A policy modification to CPB 0147 can expand or contract that experimental list.

The real risk for billing teams is billing for a service that was covered under the previous version of CPB 0147 but has been reclassified under the April 1, 2026 update. That's a retroactive denial waiting to happen if you don't update your charge capture and prior auth screening.

Because the full modified policy text isn't available in this data release, you need to pull the updated CPB 0147 directly from Aetna's clinical policy bulletins before the effective date. Don't rely on what was true in 2025. Confirm the current covered and non-covered designations and update your team accordingly.

Coverage Indications at a Glance

The policy data available for this update does not include a code-level breakdown of covered versus non-covered indications. The table below reflects the general clinical framework Aetna applies to RSD/CRPS under CPB 0147, based on the policy's historical structure. Confirm each row against the updated policy text before April 1, 2026.

Aetna Reflex Sympathetic Dystrophy Billing Guidelines and Action Items 2026

Here's what your billing team should do before April 1, 2026.

CPT, HCPCS, and ICD-10 Codes for Reflex Sympathetic Dystrophy Under CPB 0147

The policy data available for this update does not include specific CPT, HCPCS, or ICD-10 codes. Aetna's CPB 0147 policy document itself contains the authoritative code list — pull it directly from Aetna's clinical policy bulletin library to get the current covered and non-covered codes under the April 1, 2026 modified policy.

What you should expect to find when you review the full CPB 0147:

• CPT codes for sympathetic nerve blocks, spinal cord stimulation trials and implants, neurostimulator programming, and pain management evaluation and management visits
• HCPCS codes for any durable medical equipment or implantable neurostimulator devices covered under the policy
• ICD-10-CM codes for CRPS Type I (historically G90.5x series) and CRPS Type II (causalgia, historically G56.4x and G57.7x series), as well as RSD-related diagnosis codes

Do not build your billing guidelines on the code set from the previous version of CPB 0147. The modification effective April 1, 2026 may add, remove, or reclassify codes. Build your charge capture and prior auth workflows from the updated document.